Welcome to Sopharma AD A Prominent Name in Public Healthcare!
Back to Sopharma Home page Contact us  
Welcome to www.sopharma.com
16 Iliensko Chausee St.
Sofia, Bulgaria 1220
 


Other Drugs

. Natrium citricum
. EDTA-Calcium Dinatrium


Phytochemical Products from Plant origin

. Tribestan
Phytin
Carsil
Nivalin
Tabex


Pharmaceutical substances

. Silymarin
. Cytisine
. Esculin
. Galantamine bromide
. Glaucin hydrobromide
. Phytin
. Peflavit
. Tribulus terrestris
. Valerian dry extract


Pharmaceutical products

Fifteen categories
 

 

 

 

MELLIVENON

 
 
StockNo Product description Status
EB0280-401-01 MELLIVENON OINTMENT 18 G
EB0280-401-05 MELLIVENON LINIMENT W CAMPHOR 100 G
 
COMPOSITION:
Standardized bee venom 960 IU, Benzyl ester of nicotinic acid 0.1 g, Camphor 3 g, Chloroform 25 g in liniment.
Standardized bee venom 700 IU, Vitamin H 0.99 g, Benzyl ester of nicotinic acid 0.36g, Nonylvanylamide 0.072 g, Lavender oil 0.126 g in ointment.

ACTION:
Bee venom is a complex of biologically active substances, some of them with verified therapeutic effect, e.g. enzymes, hyaluronidase and phospholipase A, peptides melitin and apamin, hiostamine, choline, etc. the action of the enzymes is particularly favourable for inflammatory processes in and around the joints. Its effect on the pituitary gland-adrenals system is particularly significant for its therapeutic action, the consequence being corticoid hormone release. Mellivenon treatment has certain advantages over the administration of cortisone agents, as the physiological systems of the organism are activated, not leading to the undesired adverse effect following long-term administration of cortisone agents. The enzymes hyaluronidase and phospholipase A have a favourable effect on the inflammatory processes in joints, nerves, vascular walls, etc., reducing the reaction of connective tissue and their anticoagulant action. Bee venom reversibly blocks the sympathetic ganglia, which explains its vasodilatory action in diseases of the peripheral arteries. Benzyl ester of nicotinic acid enhances the vasodilatory action. The revulsive action of mellivenon liniment is intensified by camphor, which is followed by a light analgesia. Chloroform, topically applied in higher concentration, blocks the peripheral sensory receptors which explains its local pain-relieving action.

INDICATIONS:
Reduction of pain and inflammatory processes in joints and muscles: in rheumatology - various inflammatory and degenerative articular and periarticular diseases; in neurology - myositis, neuritis, neuralgia, lumbago, sciatica, radiculitis, etc.; vascular diseases - endarteritis, atherosclerosis of limbs, thrombophlebitis, acrocyanosis, Raynard's disease and other disturbances in peripheral circulation; non-purulent inflammatory infiltrations, muscle stiffness after sports, sequelae of sprain, dislocation, contusion, sport, occupational, etc. traumas, rehabilitation procedures.

CONTRAINDICATIONS:
Acute infectious diseases, purulent processes, acute stages of inflammatory articular diseases, enhanced susceptibility (idiosyncrasy) to bee venom, cachexia, pregnancy. Do not administer to children below the age of 5.

SIDE EFFECTS:
The side effects of bee venom are due to its histamine-like action. Bee secretion is of two types: acid - caused very likely by the local reaction (pain, hyperemia, edema, etc.) and alkaline - causing convulsions. The general reaction of the venom can be manifested in indisposition, shivers, headache, nausea, vomiting, elevated body temperature, and in enhanced susceptibility - urticaria, palpitation, accelerated pulse, articular pain, convulsions, etc.

DOSAGE AND ADMINISTRATION:
Hypersensitivity test should be performed prior to the initiation of the treatment - 2-3 liniment drops or 2-3 mm ointment squeezed out of the tube are rubbed upon 2-3 cubic cm on the skin of the forearm. In the absence of reddening, itching and swelling at the site of the application till the 24th h the treatment continues with the rubbing of small amounts of the agent upon the affected area daily in the morning and evening. The amounts of the agent rubbed is gradually increased depending both on the character of the disease and on skin tolerance till attaining the optimal therapeutic dose which does not usually exceed 1/3 of the content of the vial or tube. To enhance the revulsive effect, woolen cloth or flannelette is put upon the rubbed area. That piece of cloth is not washed or changed till the end of the treatment. The agent should be lightly rubbed without massage in case of thrombophlebitis. The duration of the treatment is from 2 to 8 weeks. After the agent has been rubbed into the skin, hyperemia can occur at the site of the application for several hours.

MEDICINAL FORM AND PACKAGE:
Liniment with camphor in vials of 100 g.
Ointment in tubes of 18 g.

STORAGE:
In a cool place (5-15° C) in tightly closed vials and tubes.

EXPIRY:
2 (two) years.

 

 

Central nervous system Bellergamin Centrophenoxine Chlorazin Cinnarizine Diazepam Haloperidol Lydol Morphine Natrium bromatum Phenobarbital Piracetam Tempalgin Tilidine adrenaline Atropine Lidocaine Nivabex Nivalin Pymadin Tabex Cardiovascular Antistenocardin Atenolol Captopril Chlophadon Chlophazolin Diltiazem Furosemide Isocor Naniprus Pentofyllin Pharmacynon Vasopren Digestive system Ranitidine Sopral Pulmonary system Bromhexin Broncholytin Codterpin Dimex Glauvent Salbutamol Sophafyllin Amidophen Analgin Feloran Indomethacin Paracetamol Piroxicam Buscolysin Papaverine Antibiotic Amikacin Chlorquinaldol Ethambutol Gentamicin Rimicid Progesterone Testosterone Allergosan Ketotifen Vitamins, Minerals & Enzymes Calcium Phospho C Deavit Deflamol Peflavit C Vitamins Furotalgin Pilocarpine Rhinolex Sulfacetamide Mycodermin Revulsan Univertan Zinc ointment Phytin Tribestan Antistrumin Bisacodyl Calcium gluconicum Glibenclamide Methilprednisolone Natrium citricum Natrim chloratum Phlebescin

© 1999-2001 Sopharma USA Corporation. All rights reserved.
Copyright, Trademark, Disclaimer and Privacy statement.

A service of Bulgarian Pharmaceutical Group Ltd.

EB0280 01/28/2001